SUMMIT, N.J | Bristol-Myers Squibb buying Celgene in $74B deal

3Jan - by Editor - 0 - In STL.News

SUMMIT, N.J. —Jan 03, 2019  —Bristol-Myers Squibb is buying Celgene in a cash-and-stock deal valued at about $74 billion.

Shareholders of Celgene Corp., based in Summit, New Jersey, will receive one share of the cancer drug maker, plus $50 in cash for each share they own. They’ll also receive one tradeable contingent value right for each Celgene share, allowing the holder to receive a payment when future regulatory milestones are hit.

Continue reading SUMMIT, N.J | Bristol-Myers Squibb buying Celgene in $74B deal at STL.News.

Source link